COMMUNIQUÉS West-GlobeNewswire

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
26/02/2024
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023 with $366.3 million [...]
Travere Therapeutics to Present at Upcoming Investor Conferences
26/02/2024
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in March: Cowen 44 th Annual [...]
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
26/02/2024
MELBOURNE, Australia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC ( [...]
HWH International Inc. Acquires Café in South Korea, Unveiling Second Hapi Cafe Outlet
26/02/2024
Bethesda, MD, Feb. 26, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH”) (Nasdaq: HWH) proudly announces the acquisition of a café in Seocho-gu, South Korea, marking the launch of its second Hapi Cafe outlet in [...]
SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance
26/02/2024
SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results [...]
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
26/02/2024
• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) expected [...]
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
26/02/2024
Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing [...]
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
26/02/2024
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license [...]
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
26/02/2024
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]
GeneDx to Participate in 44th Annual Cowen Health Care Conference
26/02/2024
STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in [...]
IO Biotech to Present at 44th Annual Cowen Health Care Conference
26/02/2024
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced [...]
Lyell Immunopharma Announces Participation in March Investor Conferences
26/02/2024
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with [...]
Clover Health to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
26/02/2024
FRANKLIN, Tenn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report fourth quarter and full year 2023 [...]
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
26/02/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS [...]
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
26/02/2024
The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) [...]
Xtant Medical to Present at the TD Cowen 44th Annual Healthcare Conference
26/02/2024
BELGRADE, Mont., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today [...]
Compass Pathways to participate in upcoming TD Cowen investor conference
26/02/2024
LONDON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that [...]
STRATA Skin Sciences Announces Successful Amendment to Credit Agreement with MidCap Financial
26/02/2024
–Amends certain financial covenants to enhance liquidity and financial flexibility– –Ensures alignment with the Company’s current and future business operations– HORSHAM, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- STRATA [...]
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
26/02/2024
CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 [...]

Pages